All data are based on the daily closing price as of September 18, 2025
g
Green Cross Holdings
005250.KO
11.24 USD
-0.20
-1.75%
Overview
Last close
11.24 usd
Market cap
505.19M usd
52 week high
12.96 usd
52 week low
8.17 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
0.314
Price/Book Value
0.72
Enterprise Value
1.59B usd
EV/Revenue
0.9741
EV/EBITDA
5.8954
Key financials
Revenue TTM
1.64B usd
Gross Profit TTM
476.55M usd
EBITDA TTM
95.87M usd
Earnings per Share
N/A usd
Dividend
0.36 usd
Total assets
3.07B usd
Net debt
1.05B usd
About
Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; and small molecules for gangliosidosis andalagille's syndrome. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies, and clinical trials. Green Cross Holdings was founded in 1967 and is headquartered in Yongin-Si, South Korea.